
Thursday, July 03, 2025 3:00:52 PM
https://www.globenewswire.com/news-release/2025/06/30/3107830/0/en/Jupiter-Neurosciences-Showcases-Nugevia-PWR-Mitochondrial-Optimization-Supplement-Designed-to-Boost-Energy-Endurance-and-Recovery.html
=================
Jupiter Neurosciences Unveils Nugevia™ GLO: A Breakthrough in Cellular Skin Health, Backed by Patented Pharmaceutical Science
https://finance.yahoo.com/news/jupiter-neurosciences-unveils-nugevia-glo-120000709.html?guccounter=1&guce_referrer=aHR0cHM6Ly9kdWNrZHVja2dvLmNvbS8&guce_referrer_sig=AQAAAJeEVM9KLf4BVOujCNJY4jlBJmM4tD5WPFb25DnQFZS3bgnJFwcGVfcTXi8nFBeqKrWBz93daRnaSg5yVjbnJSI5sfo29CC5TfufUj-cy9WTcbqheU4ieJ-fVgN7D-dSo_WNfeiecUj2rYD_2rKf59CwTTeNZKMvphI55fTXEziZ
=================
Jupiter Neurosciences to launch mitochondrial health supplement this fall
https://www.investing.com/news/company-news/jupiter-neurosciences-to-launch-mitochondrial-health-supplement-this-fall-93CH-4117651
=================
About Jupiter Neurosciences, Inc.
Jupiter Neurosciences is a clinical-stage pharmaceutical company pursuing a dual-path strategy to address neuroinflammation and promote healthy aging. The Company is advancing a therapeutic pipeline targeting central nervous system (CNS) disorders and rare diseases, while also expanding into the consumer longevity market with its Nugevia™ product line. Both efforts are powered by JOTROL™, Jupiter’s proprietary, enhanced resveratrol formulation that has demonstrated significantly improved bioavailability. Nugevia brings clinical-grade science to the supplement space, supporting mental clarity, skin health, and mitochondrial function. The Company’s prescription pipeline is focused broadly on CNS disorders, presently with a Phase IIa in Parkinson’s disease, includeing indications such as Alzheimer’s Disease, Mucopolysaccharidoses Type I, Friedreich’s Ataxia, and MELAS. More information may be found on the Company’s website www.jupiterneurosciences.com.
$JUNS 💹
Don't invest what you can't afford to lose. Always do your own DD. INV4$
Recent JUNS News
- Form 8-K - Current report • Edgar (US Regulatory) • 07/10/2025 09:08:19 PM
- Jupiter Neurosciences Regains Compliance with Nasdaq Minimum Bid Price Requirement • GlobeNewswire Inc. • 07/10/2025 08:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/09/2025 08:40:39 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/08/2025 01:28:09 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/08/2025 01:28:07 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/04/2025 12:56:52 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/01/2025 11:55:51 PM
- Jupiter Neurosciences Showcases Nugevia™ PWR: Mitochondrial Optimization Supplement Designed to Boost Energy, Endurance, and Recovery • GlobeNewswire Inc. • 06/30/2025 07:15:00 PM
- Jupiter Neurosciences Unveils Nugevia™ GLO: A Breakthrough in Cellular Skin Health, Backed by Patented Pharmaceutical Science • GlobeNewswire Inc. • 06/27/2025 12:00:00 PM
- Jupiter Neurosciences Names Golf Legend Annika Sörenstam as First Nugevia™ Brand Ambassador • GlobeNewswire Inc. • 06/23/2025 12:00:00 PM
- Jupiter Neurosciences Launches Nugevia™: A Premium Longevity and Performance Supplement Line Grounded in Clinical Science • GlobeNewswire Inc. • 06/09/2025 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/21/2025 04:38:15 PM
- Jupiter Neurosciences Highlights Upcoming Milestones in Shareholder Letter • GlobeNewswire Inc. • 04/08/2025 12:00:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/28/2025 09:01:29 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/25/2025 09:16:25 PM
- Jupiter Neurosciences and Aquanova AG Announce Strategic Collaboration to Develop Longevity and Healthspan Products • GlobeNewswire Inc. • 03/04/2025 01:00:00 PM
- Jupiter Neurosciences Addresses Market Volatility as it Remains Focused on Advancing Clinical and Commercial Milestones • GlobeNewswire Inc. • 02/04/2025 02:25:00 PM
- Jupiter Neurosciences Announces JOTROL Manufacturing Agreement with Catalent to Support Phase 2a Parkinson’s Trial • GlobeNewswire Inc. • 02/03/2025 01:00:00 PM
- Jupiter Neurosciences Partners with Zina Biopharmaceuticals to Advance Phase 2a Parkinson’s Trial • GlobeNewswire Inc. • 01/30/2025 01:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/24/2025 07:33:53 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/24/2025 07:31:28 PM
- Jupiter Neurosciences Announces Strategic Focus on NLRP3 Pathway in Future JOTROL™ Trials • GlobeNewswire Inc. • 01/13/2025 01:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 12/23/2024 09:46:40 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/20/2024 12:00:15 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/19/2024 10:00:18 PM
Fifty1 AI Labs' REVIVE Clinical Trial Redefines Long COVID Treatment, Pioneering AI-Driven Therapies and Propelling Fifty 1 Labs, Inc. Toward $50M Valuation and Global Biotech Leadership • FITY • Jul 10, 2025 8:30 AM
Aspire Biopharma Holdings, Inc., Announces Positive Consumer Feedback from Company Sampling of BUZZ BOMB™, its New Sublingual Pre-Workout Supplement • ASBP • Jul 9, 2025 9:15 AM
Breaking Through: Systemic Genetic Medicines for Hard-to-Treat Cancers • IBRX • Jul 9, 2025 9:00 AM
Fifty 1 Labs, Inc. Announces Bold Expansion Plan Powered by Nobel Prize Laureate Management Team, Cutting-Edge AI Healthcare Innovation and $350K Leadership Investment • FITY • Jul 8, 2025 8:30 AM
Avant Technologies and Partner, Ainnova, Launch Transformative Preventative Care Model for Chronic Patients Across Latin America • AVAI • Jul 8, 2025 8:00 AM
Precision Genetic Medicine Platform Could Disrupt Standard of Care in Metastatic Cancer, Other Indications of Unmet Needs • CLDI • Jul 7, 2025 9:00 AM